A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease (AMAY)
Status:
Not yet recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect, safety, tolerability, and how well
mirikizumab absorbs into the body of pediatric participants with Crohn's disease.
Study periods for the intervention-specific appendix (ISA) will be as follows:
- A 12-week induction period
- A maintenance period from Week 12 to Week 52, and
- A safety follow-up period up to 16 weeks
The study will last about 74 weeks and may include up to 19 visits.